Association of autoimmunity with survival in patients with recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab
Panagiota Economopoulou(National and Kapodistrian University of Athens), Amanda Psyrri(National and Kapodistrian University of Athens), Niki Gavrielatou(National and Kapodistrian University of Athens), Μaria Anastasiou(National and Kapodistrian University of Athens), Stavros Gkolfinopoulos(National and Kapodistrian University of Athens), George Kavourakis(National and Kapodistrian University of Athens), George Papaxoinis(St Savas Hospital), Ioannis Kotsantis(National and Kapodistrian University of Athens), Ioannis G. Panayiotides(National and Kapodistrian University of Athens)
Cited by 17
Related Papers
Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
|The Lancet Oncology|2021|618
Head and neck squamous cell cancer and the human papillomavirus: Summary of a National Cancer Institute State of the Science Meeting, November 9–10, 2008, Washington, D.C.
|Head & Neck|2009|265
Primary gastrointestinal non-Hodgkin's lymphoma: A clinicopathologic study of 128 cases in Greece. A Hellenic Cooperative Oncology Group study (HeCOG)
|Leukemia & lymphoma/Leukemia and lymphoma|2006|160
Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study
|Annals of Oncology|2022|148
Activation of Wnt Signaling Pathway by Human Papillomavirus E6 and E7 Oncogenes in HPV16-Positive Oropharyngeal Squamous Carcinoma Cells
|Molecular Cancer Research|2010|120